Nexalin Technology, INC 8-K filings

Nexalin Technology, Inc. has amended its office lease to extend the term and expand its headquarters in Houston, Texas.

Nexalin Technology, Inc. has received a delisting notice from Nasdaq due to failure to meet minimum bid price and stockholders equity requirements, with an appeal pending.

Nexalin Technology, Inc. has adopted Second Amended and Restated Bylaws, revising corporate governance procedures including stockholder meeting requirements and director nominations.

Nexalin Technology acquires PONM, Inc. to integrate AI-driven digital health platform supporting its HALO Clarity program and NeuroCare virtual clinic.

Nexalin Technology has engaged Lindus Health to conduct a 160-participant pivotal clinical trial for its HALO Clarity device to support a De Novo FDA submission.

Nexalin Technology, Inc. announced the advancement of its pivotal clinical trial for the HALO Clarity device, targeting moderate to severe insomnia, to support a planned de novo FDA submission.

Nexalin Technology received a Nasdaq deficiency notice for failing to maintain the minimum $1.00 bid price, initiating a 180-day compliance period.

Nexalin Technology, Inc. presents its updated investor strategy, highlighting advanced frequency neurostimulation devices targeting a $60 billion global mental health market.

Nexalin Technology, Inc. increased its at-the-market equity offering program to allow for the sale of up to $10 million in common stock.

Nexalin Technology, Inc. announced the expiration and delisting of its warrants, which were exercisable at $4.15 per share, from the Nasdaq Stock Market.

Nexalin Technology, Inc. announced the appointment of Justin Van Fleet, a seasoned public accounting expert, as its new Chief Financial Officer, effective August 1, 2025.

Nexalin Technology, Inc. announced the appointment of Justin Van Fleet as its new Chief Financial Officer, effective August 1, 2025, with an annual base salary of $250,000 and significant equity awards.

Nexalin Technology, Inc. announced that its shareholders approved all proposals at the Annual Meeting held on July 16, 2025, including the election of five directors, an amendment to the 2023 Equity Incentive Plan, and the ratification of its independent public accounting firm.

Nexalin Technology, Inc. announced the closing of a partial exercise of its over-allotment option, generating $312,000 in gross proceeds from the sale of 240,000 common shares at $1.30 per share.

Nexalin Technology, Inc. has announced the pricing of a $5.0 million underwritten public offering of 3,850,000 shares of its common stock at $1.30 per share.

Nexalin Technology amended its equity distribution agreement to reduce the maximum offering price of its common stock through an at-the-market program to $3.1 million.

Nexalin Technology, Inc. has replaced Marcum LLP with CBIZ CPAs P.C. as its independent registered public accounting firm, effective April 16, 2025.

Nexalin Technology announces that its registration statement on Form S-1 has been declared effective by the SEC, covering the issuance of up to 2,798,613 shares of common stock related to warrants and shares issued to Maxim Partners.

Nexalin Technology has successfully regained compliance with Nasdaq's minimum bid price requirement, a key step for continued listing.

Nexalin Technology has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, putting its listing at risk.

Nexalin Technology has appointed Carolyn Shelton as Senior Vice President of Quality, Regulatory, and Clinical Affairs, effective September 16, 2024.

Nexalin Technology held its annual meeting on August 26, 2024, where shareholders elected five directors, approved an amendment to the 2023 Equity Incentive Plan, and ratified the appointment of Marcum LLP as the independent auditor.

Nexalin Technology Inc. reports the resignation of Michael Nketiah, Senior Vice President of Clinical, Quality, & Regulatory Affairs, effective August 16, 2024.

Nexalin Technology believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement following a recent public offering of 3 million shares.

Nexalin Technology successfully closed a public offering of 3,000,000 shares, raising approximately $5.25 million in gross proceeds.

Nexalin Technology has priced a public offering of 3,000,000 shares of common stock at $1.75 per share, expecting gross proceeds of approximately $5.25 million.

Nexalin Technology has received regulatory approval from the Brazilian Health Regulatory Agency to sell its Gen-2, 15 milliamp neurostimulation device in Brazil.

Nexalin Technology, Inc. received a notification from Nasdaq regarding non-compliance with minimum stockholders' equity requirements and is preparing a plan to regain compliance.

Nexalin Technology, Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the exchange.

Nexalin Technology announced positive clinical results for its neurostimulation device and progress on its new Gen-3 HALO Clarity & Virtual Clinic model.